Dr. Marsh's talk will help attendees to understand:
· the rational for transitioning medicine delivery from therapeutics to diagnostic focus;
· the definition of Wellness and how diagnostic capabilities might impact this field;
· what is meant by precision medicine.
Clay Marsh, M.D. is Executive Director of the Center for Personalized Health Care and Vice Dean and Senior Associate Vice President for Research at the College of Medicine. He is also Professor of Internal Medicine in the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Internal Medicine and is board certified in Pulmonary and Critical Care Medicine. He is the current director of the Center for Critical Care and Respiratory Medicine, one of six signature programs at OSU Medical Center, where he has implemented systems approaches to adherence to evidence-based guidelines to improve care delivery. He is cross-appointed in five basic science departments and graduate programs.
Dr. Marsh is focused at understanding deep biology underlying human health and disease and has a 17 year history of consecutive funding from NIH and regularly serves on NIH study sections. He leads the efforts in Personalized Health Care at The Ohio State University, where he and the senior leadership are leading the effort in transforming health care delivery by creating pilot programs in wellness and chronic disease testing disruptive solutions that result in lower cost and higher quality/outcomes. Under his direction, OSU is a partner in the Coriell Institute's Personalized Medicine Collaborative and led OSU's efforts in partnering with the Institute for Systems Biology to form the P4 Medicine Institute. He has been listed in America's Best Doctors© for each of the past 8 years. He has mentored over 50 M.D., M.D. /Ph.D. and Ph.D. doctoral students, post-doctoral researchers and junior faculty.
Dr. Marsh is a member of the board of directors for the Personalized Medicine Coalition and on the executive board of the Utah Personalized Medicine Summit. He is the former director of the scientific board and past Chair of the Board of Directors of the Stanley Sarnoff Foundation for Cardiovascular Medicine and is on the National Advisory Board for the Pulmonary Bioinitiative for Lung Health and Disease with Battelle Memorial Institute and the Institute for Systems Biology and is an elected member of the American Society for Clinical Investigation. Dr. Marsh has published over 100 papers in peer-reviewed journals and maintains an active laboratory and clinical practice at Ohio State University.
To view the complete agenda and list of speakers, visit: http://www.triconference.com/
As part of the Molecular Med TRI-CON 2013, attendees have access to a partnering forum, 5 symposia, 18 short courses, and 12 core programs. The event attracts than 3,000 attendees and provides attendees an opportunity to interact with each other in the shared exhibit/poster hall, plenary keynotes and social functions.
Registration discounts are available until January 11, 2013. For complete event details visit: http://www.triconference.com/
To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, email@example.com.
Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi at firstname.lastname@example.org.
About Cambridge Healthtech Institute (www.chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.